Skip to NavigationSkip to content

Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer

Published on 16/01/20 at 11:52am

It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured recommendation from NICE  for the treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer in adult patients with a BRCA1 or BRCA2 mutation.

Data supplied in support of the case for the drug’s recommendation demonstrated that Lynparza presented a progression-free survival benefit of 19.1 months, compared to 5.5 months for placebo.

The decision means that Lynparza tablets will now be made available to NHS patients in England and Wales who have previously undergone at least three courses of platinum-based chemotherapy.  

While the therapy meets NICE’s end-of-life criteria and was deemed cost-effective in this group, it does not in patients who have only received two courses. As a result, NICE believes it has the potential to be cost-effective and has asked for further confirmatory data on overall survival benefit.

In the meantime, it has recommended that the drug be made available via the Cancer Drugs Fund in this patient population, which is estimated to be around 1,100.

NICE previously recommended Lynparza in capsule formulation for patients with a BRCA mutation who have previously received at least three courses of platinum-based chemo.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches